AMD
(Age-Related Macular Degeneration)
Understanding Age-Related Macular Degeneration (AMD)
Age-Related Macular Degeneration (AMD) is a leading cause of vision loss among older adults. It is a progressive disease that primarily affects the macula—the central part of the retina responsible for sharp, detailed vision needed for tasks like reading, driving, and recognizing faces. As the macula deteriorates, the ability to see fine details becomes impaired, making everyday activities challenging.
Globally, AMD affects over 190 million people, with cases projected to reach 288 million by 2040. In India, studies show 12.5% of individuals aged 51-60 years are affected by AMD, rising to 41.7% in those aged 71-80 years.
Challenges in Early Detection
In its early stages, AMD often develops without noticeable symptoms. Some individuals may experience mild blurriness or difficulty seeing in low light, but these signs are easy to overlook. Limited awareness and restricted access to advanced retinal imaging and specialists further delay detection. Without timely intervention, AMD can progress to advanced stages, resulting in permanent vision loss.
Challenges in Early Detection
In its early stages, AMD often develops without noticeable symptoms. Some individuals may experience mild blurriness or difficulty seeing in low light, but these signs are easy to overlook. Limited awareness and restricted access to advanced retinal imaging and specialists further delay detection. Without timely intervention, AMD can progress to advanced stages, resulting in permanent vision loss.
FH-POISE and AMD Detection
FH-POISE enhances AMD diagnosis by combining advanced imaging with precise analysis.
How FH-POISE Works
Integrated Image Insights
Analyzes retinal images to detect subtle changes linked to both dry and wet AMD.
Comprehensive Reporting
Provides detailed, AI-generated insights to help healthcare professionals identify early-stage AMD and track disease progression.
Early Intervention
Enables timely detection and treatment planning, helping to preserve vision and improve patient outcomes.
While AMD cannot be reversed, early diagnosis and proactive management can slow its progression. FH-POISE supports healthcare providers with precise, data-driven insights, improving clinical decisions and enhancing the quality of life for those affected by AMD.
References and External Links
- Age-related macular degeneration and the aging eye
https://pmc.ncbi.nlm.nih.gov/articles/PMC2682379/ - Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
https://www.thelancet.com/journals/lango/article/PIIS2214-109X(13)70145-1/fulltext - Indian Journal of Clinical and Experimental Ophthalmology
https://www.ijceo.org/html-article/11521 - Age-Related Macular Degeneration (AMD)
https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration - Symptoms of AMD
https://www.mdfoundation.com.au/about-macular-disease/age-related-macular-degeneration/how-do-you-know/
